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Abstract
Purpose The purpose of the study is to assess the
contribution of 18F-fluoro-ethyl-tyrosine (18F-FET) positron
emission tomography (PET) in the delineation of gross
tumor volume (GTV) in patients with high-grade gliomas
compared with magnetic resonance imaging (MRI) alone.
Materials and methods The study population consisted of
18 patients with high-grade gliomas. Seven image seg-
mentation techniques were used to delineate 18F-FET PET
GTVs, and the results were compared to the manual MRI-
derived GTV (GTVMRI). PET image segmentation techni-
ques included manual delineation of contours (GTVman), a
2.5 standardized uptake value (SUV) cutoff (GTV2.5), a
fixed threshold of 40% and 50% of the maximum signal
intensity (GTV40% and GTV50%), signal-to-background
ratio (SBR)-based adaptive thresholding (GTVSBR), gra-
dient find (GTVGF), and region growing (GTVRG).
Overlap analysis was also conducted to assess geographic
mismatch between the GTVs delineated using the different
techniques.
Results Contours defined using GTV2.5 failed to provide
successful delineation technically in three patients (18% of
cases) as SUVmax<2.5 and clinically in 14 patients (78% of
cases). Overall, the majority of GTVs defined on PET-based
techniques were usually smaller than GTVMRI (67% of
cases). Yet, PET detected frequently tumors that are not
visible on MRI and added substantially tumor extension
outside the GTVMRI in six patients (33% of cases).
Conclusions The selection of the most appropriate 18F-FET
PET-based segmentation algorithm is crucial, since it
impacts both the volume and shape of the resulting GTV.
The 2.5 SUV isocontour and GF segmentation techniques
performed poorly and should not be used for GTV
delineation. With adequate setting, the SBR-based PET
technique may add considerably to conventional MRI-
guided GTV delineation.
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Introduction
The standard treatment of high-grade glioma consists of
surgery and radiation therapy (RT) with concomitant and
adjuvant chemotherapy [1]. Unfortunately, the demonstrat-
ed benefit of RT does not extend to cure for the vast
majority of patients. As RT is the backbone of the treatment
strategy, defining the precise gross tumor volume (GTV) is
of paramount importance. For the diagnosis of primary
brain tumors, magnetic resonance imaging (MRI) and
computed tomography (CT) are the imaging modalities of
choice [2, 3]. As such, these are also used in the
postoperative setting for GTV delineation [4]. However, a
real measure of tumor extension in high-grade gliomas is
quite difficult with either modality. In the particular case of
recurrent gliomas, MRI was found to have a low specificity
to distinguish between side effects of therapy and tumor
recurrence corresponding to only 50–53% [5, 6].
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Recently, positron emission imaging (PET) was recognized
as a valuable tool in the primary and secondary diagnosis of
high-grade gliomas [3]. 18F-fluoro-deoxy-glucose (FDG) as
probe is not very useful in the diagnosis of brain tumors,
since the normal brain has a high metabolic activity and thus
does not allow differentiating between normal cerebral tissue
and tumors [7]. Radiolabeled amino acids can pass the
blood–brain barrier independently of its disturbance. A
variety of 11C- and 18F-labeled amino acids such as 11C-
methionine (11C-MET) and 18F-fluoro-ethyl-tyrosine (18F-
FET) have been studied for potential use in oncologic PET
[8]. Most brain tumors show an increased uptake of amino
acids compared with normal brain. In particular, the uptake
of 18F-FET by brain tumors especially by high-grade glioma
cells is intense relative to the low uptake in normal cerebral
tissue [9]. 18F-FET PET showed its potential in the detection
of primary and recurrent brain tumors with high sensitivity
and specificity [5, 10–13].
One of the most difficult issues facing PET-based
radiation therapy treatment planning is the accurate delin-
eation of target regions from typical noisy functional
images [14]. The major problems encountered in functional
volume quantitation are image segmentation and imperfect
system response function. Image segmentation is defined as
the process of classifying the voxels of an image into a set
of distinct classes. The difficulty in image segmentation is
compounded by the low spatial resolution and high noise
characteristics of PET images. Medical image segmentation
has been identified as the key problem of medical image
analysis and remains a popular and challenging area of
research. Despite the difficulties and known limitations,
several image segmentation approaches have been proposed
and used in clinical setting. These include thresholding,
region growing, classifiers, clustering, edge detection,
Markov random field models, artificial neural networks,
deformable models, atlas-guided, and many other
approaches [15, 16].
At present, various methods are used in practice to
delineate PET-based target volumes [16–25]. The manual
delineation of target volumes using different window level
settings and look up tables is the most common and widely
used technique in the clinic. However, the method is highly
operator-dependent and is subject to high variability
between operators [20, 26]. Semiautomated or fully
automated delineation techniques might offer several
advantages over manual techniques by reducing operator
error/subjectivity, thereby improving reproducibility. How-
ever, despite the remarkable progress that automated image
segmentation has made during the last few years, perfor-
mance validation in a clinical setting remains the most
challenging issue [27]. When using clinical data where the
ground truth is not known a priori, it is generally unaccept-
able to use an imaging modality as gold standard against
which results from another imaging modality are compared.
Therefore, the objective of this study is to compare GTVs
delineated using structural MRI with those obtained using
various strategies for 18F-FET PET-based image segmenta-
tion techniques for high-grade gliomas in the absence of a
gold standard providing the independent truth.
Material and methods
Patients
This prospective study was approved by the institutional
ethical committee. A signed informed consent was obtained
from all patients participating in the study protocol. The 20
patients were refereed to the Division of Nuclear Medicine
of Geneva University Hospital between July 2006 and
December 2007. The mean age of the patients was 54 years.
The clinical characteristics and referral patterns of the
patient population are summarized in Table 1. Given that
18F-FET tracer is not registered in Switzerland, it was
administered under the ruling of “compassionate use”,
which requires approval on a patient by patient basis by
the Swiss federal authorities (Swissmedic and the Federal
Office of Public Health). Two patients (one with brainstem
tumor and one with anaplastic astrocytoma) were excluded
due to technical problems. The remaining 18 patients had
histologically proven high-grade gliomas (grade III, 4
patients; grade IV, 14 patients). The inclusion criteria for
the trial were the diagnosis of inoperable high-grade glioma
Table 1 Clinical characteristics and referral patterns of the patient
population included in the study protocol (n=18)
Characteristics Number (%)
Age (year)
Mean 54, range 20–75
Sex
Men 8 (44)
Women 10 (56)
Karnofsky performance status
100 4 (22)
90 3 (17)
80 7 (39)
70 4 (22)
Histologic characteristics
Glioblastoma WHO IV 14 (77)
Astrocytoma WHO III 2 (11)
Oligodendroglioma WHO III 1 (6)
Oligoastrocytoma WHO III 1 (6)
Indication for PET/CT
Recurrence 1 (6)
After partial resection 9 (50)
After biopsy in unresectable tumor 8 (44)
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or the suspicion of residual tumor on structural MRI
performed during the first 24 h postoperatively and/or the
intraoperative diagnosis of possible residual tumor. In eight
patients, PET scanning was performed after partial resection
of the high-grade glioma (median time 13 days) and in nine
patients after biopsy of inoperable high-grade glioma
(median time 16.5 days). One patient presented with a
recurrent anaplastic astrocytoma grade III, 4 years after partial
resection and intermittent chemotherapy with Temozolomide.
The recurrence was histologically proven by biopsy.
18F-fluoro-ethyl-tyrosine
18F-fluoro-ethyl-tyrosine was prepared according to good
manufacturing practice standards at the Centre of Radio-
pharmacy, University Hospital of Zurich, Switzerland and
delivered to our department. All patients were injected a
standard activity of 200 MBq 18F-FET, which resulted in an
average effective dose of 3.3 mSv [28].
PET/CT scanning
All patients had a diagnostic quality PET/CT scan of the
brain in radiotherapy treatment position on a dedicated
combined scanner equipped with a set of three triangulation
lasers (central and laterals) similar to those used for
standard CT-based virtual simulation. For CT scanning,
contrast enhancement was not used in this particular
population. Patient positioning was verified by individual
plastic masks. The simulation was carried out by experi-
enced radiation therapy technologists trained specially for
this purpose. PET imaging of the brain and non-enhanced
CT with 2-mm slice thickness were acquired in all patients
using a Biograph 16 PET/CT scanner (Siemens Medical
Solutions, Erlangen, Germany) operating in 3D mode.
Patients were placed in scanning position and CT imaging
performed under standard conditions using 120 kVp,
90 mAs, 16×1.5 collimation, a pitch of 0.8 and 0.5 s/
rotation. Patients were injected intravenously after 4–6h
fasting periods. Listmode PET data acquisition started
immediately following tracer injection for a total duration
of 30 min to allow a flexible choice of reconstruction
frames. The dynamic study corresponds to a single bed
position covering the head up to the second cervical
vertebral body. An additional late static acquisition
(10 min) in the same position was also performed after
the listmode study in 12 patients.
Dynamic series of 3×10 min were reconstructed using
the standard clinical protocol recommended by the manu-
facturer to define the sequence showing the highest uptake
in the brain tumors compared to the normal brain tissue.
Following Fourier rebinning and model-based scatter
correction, PET images were reconstructed using two-
dimensional iterative normalized attenuation-weighted or-
dered subsets expectation maximization (NAW-OSEM).
The CT-based attenuation correction map was used to
reconstruct the emission data. The default parameters used
were OSEM iterative reconstruction width four iterations
and eight subsets followed by a post-processing Gaussian
filter (kernel full-with half-maximal height, 5 mm).
The PET, CT, and fused PET/CT images were displayed
for review in axial, coronal, and sagittal planes. All studies
were interpreted and reviewed with knowledge of the
patient’s clinical history and results of previous imaging
studies. A team involving two experienced nuclear medi-
cine physicians and an experienced radiologist interpreted
the 18F-FET PET/CT images. A multimodality computer
platform (Syngo Multimodality Workplace, Siemens Med-
ical Solutions, Erlangen, Germany) was used for image
review and interpretation. A site of increased 18F-FET
uptake was defined as benign and unrelated to cancer when
it is located in an area corresponding to the physiologic
biodistribution of the tracer or when related to known
nonmalignant physiologic process. A focus of increased
18F-FET uptake, with intensity higher than that of
surrounding tissues, in areas unrelated to physiologic or
benign processes, was defined as malignant. All PET
studies showing at least one site of abnormal 18F-FET
uptake characterized as malignant were defined as positive.
The maximum standardized uptake value (SUVmax) was
calculated for regions of interest (ROIs) of focal hyperac-
tivity by dividing the observed activity concentration in
attenuation-corrected PET data with the injected activity per
gram body weight. The SUVmax of each lesion was
calculated for the corresponding dynamic time frame
considered by applying appropriate decay correction.
Magnetic resonance imaging
High-resolution gadolinium-enhanced three-dimensional
MR brain images were obtained for all clinical studies,
except one patient. This patient presented a contraindication
for MRI owing to the presence of two intracranial metallic
bullets. The MRI was practiced at a mean of 16.9 days
(range 7 to 35) before the PET/CT study. All patients
undergoing a partial resection had a postoperative MRI
during the first 24 h following surgery.
The MRI was performed either on a 1.5-T Gyroscan
Intera MRI scanner (Philips Medical systems, Cleveland,
OH, USA) or a 3-T Magnetom Trio MRI scanner (Siemens
Medical Solutions, Forchheim, Germany) equipped with a
standard head coil. The MRI protocol consisted of a T1-
weighted sequence (25 cm axial field of view, 7.8 s
repetition time, 256×256 matrix size, 160 axial slices with
1.1 mm slice thickness both before and 2 min. after
injection of 0.2 ml/kg gadolinium). A sagittal and coronal
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fluid attenuation inversion recovery (FLAIR) as well as a
T2-weighted axial sequence were also performed with a
slice thickness of 5 mm for each sequence. In addition, MR
spectroscopy was performed on the side corresponding to
the brain tumor and on the contralateral side.
Phantom experiment for derivation of the SBR algorithm
In diagnostic and oncological PET imaging, if the intention
is to measure the volume and uptake in a specific lesion, it
is convenient to make preliminary phantom studies on an
object of similar shape and size with the assumption that
the size, shape, location, density, and intensity of the
simulated object and surrounding tissues are comparable to
that of the patient to be measured. The SBR technique
requires calibration data that are applicable for quantifica-
tion of tumor volumes in clinical oncology. The NEMA
IEC/2001 image quality body phantom (Fig. 1A,B)
consisting of an elliptical water-filled cavity with six
spherical inserts suspended by plastic rods of volumes
0.5, 1.2, 2.6, 5.6, 11.5, and 26.5 cc (inner diameters of 1.0,
1.3, 1.7, 2.2, 2.8, and 3.7 cm) was used to derive the
parameters required for implementation of the adaptive
thresholding algorithm based on SBR estimates. The
spheres were filled with 18F activity concentration ranging
from 20 to 47 kBq/cc. The water cavity was first filled with
increasing activity of 18F to get SBRs of 10.0, 8.6, 6.9, 5.0,
3.3, and 2.1. These activity ratios were chosen to simulate
the range of SBRs observed in clinical conditions. For all
SBR ratios, 15 min PET data acquisitions were performed
on the same Biograph PET/CT scanner used for patient
studies (Siemens Medical Solution, Erlangen, Germany).
The images were reconstructed using the same processing
protocol applied to clinical studies. The SBRs were
measured from all combinations of spheres and background
activity concentrations. The maximal activity of the spheres
was defined as the average activity of the eight voxels
surrounding the hottest voxel. The background activity
concentration was measured in planes containing the
spheres using eight circular ROIs with a diameter of
5 cm, where the mean value of all ROIs was considered
as background activity concentration. The diameter and
volume of each sphere was successively calculated using
increasing thresholds, where the thresholds were deter-
mined as a percentage of the maximal activity in the
spheres. The optimal thresholds which resulted in minimal
least square difference between measured and actual sphere
volumes were obtained (Fig. 2C). The smallest sphere of
0.5 cc with a diameter of 10 mm was excluded from the
analysis to avoid the significant bias of partial volume
effect owing to the limited spatial resolution of the scanner.
The measured SBR and the resultant threshold were fitted
using an inverse function (Threshold ¼ aþ b 1=SBR) to
yield the best regression parameters for the equation which
allows estimation of the optimal threshold independent of
any a priori knowledge of the lesion characteristics and
tumor location. The results were almost similar when the
SBR measurements were performed in a head-sized
phantom thus confirming the applicability of the technique
for almost all tumor locations.
Fig. 1 (A) Computed Tomogra-
phy (CT) and (B) corresponding
PET transaxial slices of the
whole-body NEMA IEC/2001
image quality body phantom
used to derive the parameters
required for implementation of
the adaptive thresholding algo-
rithm. The phantom consists of
an elliptical water filled cavity
with six spherical inserts sus-
pended by plastic rods, of inner
diameters of 1.0, 1.3, 1.7, 2.2,
2.8, and 3.7 cm. A horizontal
profile through the sphere hav-
ing a diameter of 2.8 cm illus-
trating the signal-to-background
ratio (SBR)-specific threshold
(39%) that best corresponded to
the physical diameter of the
spherical source is also
shown (C)
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Gross tumor volume delineation
Manual GTV delineation
The brain MR images were first coregistered to their
respective PET/CT images using an automated image
registration software embedded within the TrueD software
(Siemens Medical Solutions, Erlangen, Germany). A linear
rigid-body registration using a traditional nine-parameter
model was used. The same software was also used for
manual delineation of the GTV. The conventional MRI-
based GTV (GTVMRI) and the PET-based GTV (GTVman)
were delineated manually in two separate sessions by an
experienced radiation oncologist. For GTVMRI delineation,
a gadolinium-enhanced T1-weighted gradient-echo se-
quence was used. The image matrix consisted of 256×
256×160 voxels, with a resolution in the transaxial
direction of 0.97×0.97 mm2 and an axial resolution of
1.1 mm. Besides the information from the dynamic PET
series, all clinical history and previous imaging studies
including complementary MRI sequences were provided. In
a second session, the same radiation oncologist delineated
the GTVman consensually using appropriate window-level
settings for identifying the tumor from background. Clinical
interpretation as well as GTVman delineation was performed
on static images reconstructed from the listmode data in the
interval between 10 and 20 min which proved to be the
sequence resulting in the highest contrast between the
tumors and normal brain tissue.
Semiautomated PET image segmentation techniques
Six semiautomated image segmentation techniques were
used to obtain PET-derived GTVs. The GTVs were
delineated using the RT_Image software [29]. An isocon-
tour of SUV 2.5 around the tumor region was used to
obtain an SUV threshold-based cutoff GTV (GTV2.5). In
addition, a fixed threshold of 40% and 50% of the
maximum signal intensity was also used to delineate
GTV40% and GTV50%, respectively. The GTV delineation
based on region growing (GTVRG) and gradient find
(GTVGF) segmentation algorithms were obtained using
techniques described in the aforementioned reference [29].
Region growing approaches exploit the fact that voxels
which are close to each other have comparable gray values.
Region growing is a bottom–up procedure starting with a
set of seed pixels and growing to a homogeneous connected
region from each seed. The user usually selects a voxel, and
a region grows out from that seed until some criteria for
stopping growth are met. Briefly, the RG technique used in
this work finds the voxel of maximum intensity from the
seed along the projection line. The segmented region
consists of all voxels connected to the local voxel
containing maximum intensity within a 10-mm diameter
sphere that have an intensity greater than 50% of the local
maximum intensity. On the other hand, edge detection-
based approaches exploit the existence of abrupt changes in
gray level intensity values to delineate edges that are
formed at the intersection of two regions. Edge detection
techniques work relatively well on images with good
contrast between regions. An edge is marked if a significant
spatial change occurs in the second derivative. For the GF
algorithm, segmentation is performed on a region identified
as pathologic through user interaction. This region is
generated following appropriate seed selection to initiate
the above described RG technique. The algorithm used is a
variant of the Marr–Hildreth edge detector that iteratively
adjusts the contours toward a zero crossing in the second
gradient, which corresponds to a local maximum of the
gradient magnitude. Finally, the popular signal-to-back-
ground ratio (SBR)-based adaptive thresholding technique
described in [18] was used to obtain GTVSBR. The
scanner-specific parameters required for derivation of the
adaptive threshold calibration curve was obtained through
a phantom experiment with various signal to background
ratios as described in the phantom experiment section
above. For GTVSBR delineation, the maximum signal
intensity of the tumor was defined as the mean activity of
the hottest voxel and its eight surrounding voxels in a
transversal slice, whereas the mean background activity
Fig. 2 Plots of the relationship between the signal-to-background
ratio and the threshold to be applied to fit spheres of volumes ranging
between 1.2 and 26.5 cc. The data were fitted using an inverse
function of the form Threshold ¼ aþ b 1= SBR
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was obtained from a manually drawn ROI far away from
the tumor.
Tumor delineation was considered unsuccessful if the
resulting volume contained only small parts of the tumor,
substantially large parts of visually normal tissue (as
observed on GTVSBR and GTVman), or because of
technical impossibility of the contouring (e.g., SUVmax<
2.5 makes it impossible to draw a GTV2.5). The GTVs
obtained by using semiautomated delineation algorithms
were checked visually by an experienced radiation
oncologist before approval.
Statistical analysis of GTVs
To assess geographic mismatch between the GTVs delin-
eated using the different segmentation techniques, the
following overlap analysis were performed: (1) The overlap
volume of GTVMRI and GTVPET, for which overlap was
expressed as the overlap volume of GTVMRI and GTVPET
relative to GTVMRI–overlap fraction (OF) MRI [OFMRI];
(2) the overlap volume of GTVMRI and GTVPET relative to
the PET-based GTVs−overlap fraction PET [OFPET]; (3)
the volume enclosed by GTVMRI but not by GTVPET
relative to GTVMRI, which is 1−OFMRI; and (4) the volume
enclosed by GTVPET, but not by GTVMRI relative to
GTVPET, which is 1−OFPET. In addition, the overlap
volume of GTVPET and GTVSBR relative to GTVSBR was
also calculated. Statistical analyses and curve fitting were
performed using SPSS® (version 15.0, SPSS, Chicago, IL,
USA). Regression analyses were used to evaluate difference
between calculated volumes and overlap between GTVs
when using the different segmentation tools. The level of
statistical significance adopted was 0.05.
Results
Figure 2 shows plots of the threshold to be applied to fit
spheres of volumes ranging between 1.2 and 26.5 cc vs. the
SBR. The regression parameters of the inverse function
(Threshold ¼ aþ b 1=SBR) that best fitted the experi-
mental results are a=34.9 and b=48.2. Consistent with the
observations made by previous investigators [18, 30], this
relationship indicates that a higher threshold is required to
accurately estimate the actual volume of objects with low
contrast (i.e., low SBR). To avoid the slight dependence of
the threshold required to adequately measure the actual
volume of the spheres and thus the derived regression
parameters on image reconstruction technique and selected
parameters, the same reconstruction algorithm and associ-
ated parameters (number of iterations, subsets, and post-
reconstruction smoothing) used in clinical studies were
applied.
PET detected frequently tumors that are not visible on
MRI and added substantially tumor extension outside the
GTVMRI in six patients (33% of cases). Figure 3 shows one
such example where tumors were only detected on the 18F-
FET PET study and completely missed on MRI. The
comparison of GTV delineation based on MRI and seven
18F-FET PET-based GTVs is summarized in Table 2. In all
18 patients, MRI images could identify 19 lesions, whereas
FET PET images identified 24 lesions, i.e., the 18F-FET
PET images could identify five lesions which were not seen
on MRI. Out of the seven 18F-FET PET GTV segmentation
techniques only GTV2.5 and GTVGF was not successful in
four of 24 and in eight of 24 lesions delineation,
respectively, due to technical difficulties. Overall, the GTVs
delineated by 2.5 SUV isocountour (SUV2.5) and GF were
neither realistic nor comparable with other segmentation
techniques in most of the lesions, even though they were
technically feasible. The failure of GF technique in
delineating realistic GTV could be due to low and
inhomogeneous tumor uptake. Hence for the sake of
comparison of GTV delineation between MRI and other
FET PET-based techniques, the SUV2.5 and GF techniques
were excluded from further analysis.
Figure 4 shows a typical example of a patient study
presenting with a glioblastoma illustrating differences in
target-volume definition obtained using the various meth-
ods described above compared to GTVMRI. For this
particular patient (patient no. 7 in Table 2), all PET-based
techniques define almost similar contours on this plane, but
overall, the estimated lesion volume is different. Figure 5
illustrates 3-D volume rendering of the GTVs assessed
using the various segmentation techniques and overlap
analysis of the geographic match/mismatch between the
defined GTVs. Indicated are GTVMRI and three PET-based
GTVs including GTVman, GTVRG, and GTVSBR. Also
shown are the overlaps between GTVMRI and GTVman,
GTVRG, and GTVSBR, respectively. Note that for this
particular tumor, GTVman practically comprised approxi-
mately 95% of GTVMRI. Figure 6 shows the comparison of
mean absolute tumor volumes for 18 patients in only 19
lesions where MRI, manual delineation, thresholding using
40% and 50% of the maximum intensity, as well as RG and
SBR techniques were able to adequately delineate the
tumor volume (GF and SUV 2.5 were excluded in this
analysis). Error bars indicate SD on the mean. Overall,
none of the techniques yielded similar volumes relative to
GTVMRI.
The GTVs delineated using the different methods and
OFs between various segmentation tools are summarized in
Table 3. The mean volumes are for 18 patients, and only 19
lesions were similar to Fig. 6; the retained segmentation
technique were only those that were able to adequately
delineate the tumor volume (GF and SUV2.5 were excluded
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in this analysis). The mean OFMRI varied from 0.14 to 0.54
depending on the segmentation technique used, whereas the
mean OFPET varied from 0.45 to 0.67. The mean GTV
fraction was delineated by MRI, but not by PET (i.e., 1-−
OFMRI) varied between 0.46 and 0.86, whereas the mean
GTV fraction was delineated by PET, but not by MRI (1−
OFPET), which varied between 0.33 and 0.55. The mean
absolute volume, OFMRI, and OFPET for GTVman vs.
GTVSBR and GTVRG vs. GTV50% were almost similar.
OFSBR is a comparison of OF within PET-defined volumes,
which explains the lack of results for GTVMRI. The p
values are reported for OFs relative to OFSBR as obtained
by linear regression analysis.
Discussion
Among various functional imaging techniques, PET is
considered the most powerful modality for providing an
accurate, reliable, and reproducible estimate of various
physiological and metabolic parameters [31]. Visual or
qualitative assessment of PET images provides a relative
and subjective impression regarding the overall landscape
of function at the sites examined, particularly when the aim
is to delineate target volumes in radiation treatment
planning and to evaluate treatment response. For the former
application, the most critical point is image segmentation,
which is the process of identifying malignant lesions in the
PET data and delineating their spatial occupation in the
images. Image segmentation has been identified as the key
problem of medical image analysis and remains a popular
and challenging area of research. Manual and automated
segmentation of patient image volumes for the purpose of
quantifying tumor size, shape, and uptake has received
significant attention during the last decade [15]. At present,
different segmentation methods exist for PET-based target
volume delineation. Among them, manual contouring by
visual examination is the most commonly used method.
The principal drawback of this method is that, it is highly
subjective rather than objective due to various window-
level settings used by different operators and varied
perceptions of individuals owing to the inherent complexity
of the human visual system. To limit intra- and inter-
observer dependence and variability, the development of
unsupervised segmentation algorithms is highly desired.
The need for highly objective and automatic segmentation
Fig. 3 Illustration of two clinical studies where tumors were only
detected on the 18F-FET PET study and missed on structural MRI. The
images shown on the top row correspond to gadolinium enhanced T1-
weighted MRI (A), coregistered PET (B) and fused PET/MR (C) of
the first study. The same is shown in the bottom row for the second
study (D, E, and F)
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methods was largely recognized, and various groups have
formulated different algorithms for image segmentation
[16]. Segmentation by fixed thresholds of 40%, 50% of
maximum intensity levels, isocontouring of SUV2.5, adap-
tive thresholding using the signal to background ratio,
region growing, clustering, gradient-based edge detection,
and statistical Markov random field models are the most
frequently used automatic procedures.
In this study, we compared seven PET-based techniques
for delineation of GTV relative to MRI-guided derivation of
GTV. Out of the seven 18F-FET PET GTV segmentation
techniques, only GTV2.5 and GTVGF were not successful in
three of 18 and in eight of 18 patients, respectively, due to
technical difficulties. The 18F-FET PET-detected tumors
were highly heterogeneous and had quite variable signal to
background ratios. In most of the cases, the maximum
tumor uptake was low compared to typical FDG studies;
hence, the use of the empirical SUV2.5 technique seems to
be rather unrealistic as can be observed on the volumes
delineated by this method which are grossly different from
the remaining segmentation methods. Image segmentation
using GF also does not seem to be relevant, as the tumor
volumes had many signal minima and maxima combined
with low-signal uptake making the technique not ideal for
this group of patients.
From the overlap analysis, it was observed that OFMRI
decreased and OFPET increased, from GTV40% to GTVman
to GTVSBR, GTVRG, GTV50% which implies that in this
order, as the PET volume decreased, it was increasingly
incorporated within the MRI volume. Though the mean
absolute volumes, OFMRI, and OFPET of GTVman vs.
GTVSBR and GTVRG vs. GTV50% were similar, when the
analysis was done on an individual patient basis, the
geographic mismatch was found to be substantial in many
cases. The relatively small number of clinical studies
included in this work is mainly due to financial constraints
given that brain 18F-FET PET is not a reimbursed indication
in Switzerland. It should be emphasized, however, that the
number is sufficient for reliable statistical analysis thus
allowing reaching the objectives set.
Most other studies comparing GTV delineations in brain
tumors using 18F-FET [32–34] or 11C-MET [35–38] against
MRI reported that the addition of PET information
modified significantly the shape and the extension of the
GTV. The SBR-based method for GTV delineation is
arguably the only automatic PET image segmentation
Table 2 Summary of gross tumour volumes derived from MRI and estimated using the different PET image segmentation techniques
Pt. No Histology Tumour site MRI Volume (cc) 18F-FET PET Volume (cc)
GTVMRI GTVman GTVSBR GTVRG GTV40% GTV50% GTVGF GTV2.5
1 AIII Occipital 57.4 25.1 15.9 11.9 19.8 11.9 12.1 4.3
Temporal 27.6 28.3 19.3 16.1 27.9 14.7 – 1.8
2 AIII Thalamus 33.8 8.0 7.7 12.9 33.8 12.9 12.6 0.6
3 GBM Parietal – 9.7 7.4 6.1 9.8 5.8 5.4 5.6
Frontal 20.9 12.6 6.0 4.9 9.3 4.7 4.4 4.1
Frontal – 4.4 5.5 3.6 11.7 4.2 3.2 0.3
4 GBM Frontal 79.9 23.7 30.0 28.9 37.7 28.8 28.1 11.4
5 ODIII Occipital 34.1 55.2 23.1 35.8 29.3 42.5 39.7 16.2
6 GBM Frontal – 22.9 21.5 20.5 44.2 19.6 – 2.4
Parietal 19.0 10.6 8.4 7.6 13.6 7.8 7.2 3.6
7 GBM Frontal 23.9 48.9 38.4 30.9 45.8 32.2 28.3 19.4
Parietal – 3.3 2.4 1.9 3.1 1.7 1.4 1.1
8 GBM Temporal 65.4 60.8 42.7 31.8 50.8 31.8 31.2 26.2
9 OAIII Frontal 34.0 25.9 33.1 18.2 89.4 16.8 – 0.3
10 GBM Parietal 72.9 73.0 57.6 42.2 69.7 40.6 41.9 –
11 GBM Frontal 76.9 42.2 53.1 61.9 57.8 26.4 – 7.8
12 GBM Frontal 34.5 22.1 34.9 30.3 43.9 29.5 – 1.0
13 GBM Frontal 23.5 32.4 24.7 22.0 28.6 23.9 22.6 7.0
14 GBM Temporal 25.1 47.2 46.2 39.6 55.4 40.0 36.7 58.3
15 GBM Temporal 13.4 4.9 29.0 8.3 35.3 5.8 – –
16 GBM Parietal 40.7 45.3 34.2 41.8 37.0 41.7 41.4 –
Frontal – 0.7 3.8 0.9 5.1 0.9 – –
17 GBM Frontal 41.8 12.0 11.0 6.0 10.4 5.9 5.4 2.0
18 GBM Frontal 39.8 22.9 46.4 49.6 62.7 45.2 – 5.9
AIII Anaplastic astrocytoma WHO III, OAIII anaplastic oligoastrocytoma WHO III, ODIII anaplastic oligodendroglioma WHO III, GBM
glioblastoma WHO IV
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Fig. 4 (A) Gadolinium enhanced T1-weighted MRI, (B)
corresponding 18F-FET PET, and fused PET/MR (C) transaxial slices
of a clinical study with a glioblastoma showing differences in target-
volume definition. Indicated are (D) the gross tumor volume (GTV)
delineated on MRI (GTVMRI), and (E) enhanced details of PET-based
GTVs obtained by manual delineation of contours (GTVman; magen-
ta), an isocontour of a standardized uptake value (SUV) of 2.5
(GTV2.5; purple), a fixed threshold of 40% (GTV40%; green) and 50%
(GTV50%; cyan) of the maximum signal intensity, signal-to-back-
ground ratio (SBR)-based adaptive thresholding (GTVSBR; yellow),
gradient find (GTVGF; blue), and region growing (GTVRG; red)
segmentation algorithms. Note that GTVMRI overestimates the tumor
extension relative to GTVman
Fig. 5 Three-dimensional volume rendering of the gross tumor
volumes (GTVs) assessed using the various segmentation techniques
and overlap analysis of the geographic match/mismatch between the
defined GTVs. Indicated are (A) the GTV delineated on MRI
(GTVMRI), and the PET-based GTVs obtained by (B) manual
delineation of contours (GTVman), (C) region growing (GTVRG), (D)
signal-to-background ratio (SBR)-based adaptive thresholding
(GTVSBR). Also shown are the overlaps between GTVMRI relative to
GTVman (E), GTVMRI relative to GTVRG (F), and GTVMRI relative to
GTVSBR (G). Note that for this particular tumor, GTVman practically
comprised approximately 95% of GTVMRI
190 Eur J Nucl Med Mol Imaging (2009) 36:182–193
technique validated thoroughly using histologic data [39]
and was hypothesized to be the most accurate one for high
SBR levels [23]. 18F-FET and 11C-MET PET tracers have
been shown to be in a close correlation when imaging
human brain tumors [40]. A thorough assessment of the
impact of 18F-FET PET on the delineation of GTV is
lacking compared to 11C-MET PET. A prospective study
using 18F-FET PET and MRI in patients with suspected
cerebral glioma concluded that the combined use of MRI
and 18F-FET PET was clearly superior to that of MRI alone
for the noninvasive distinction of tumor tissue and
peritumoral brain tissue [6]. The combined MRI–FET
PET approach was able to image the true extent of cerebral
gliomas with a high sensitivity and specificity (93% and
94%, respectively). On the other hand, MRI alone had a
low specificity (only 53%). A tumour-to-normal brain
threshold of 1.6 for 18F-FET uptake was found the best
ratio to detect the extent of gliomas and to distinguish
between malignant and benign lesions in the brain [6, 33].
Grosu et al. were the first to show a survival benefit for
patients reirradiated for recurrent high-grade gliomas using
11C-MET PET or 3–123I-iodo-alpha-methyl-L-tyrosine
SPECT/CT/MRI image fusion in the treatment planning,
in comparison to patients treated based on MRI/CT alone
[36]. In studies for target definition using 11C-MET PET, a
threshold value of 1.7 for the tumour/normal brain index
was used [37, 38]. In addition, it was demonstrated that the
fusion between MRI and 11C-MET PET results in signif-
icantly higher specificity and accuracy in GTV delineation
compared to MRI alone. Grosu et al. compared 11C-MET
PET and MRI in resected high-grade gliomas using image
fusion for radiation therapy treatment planning and showed
that the majority of patients had a poor correlation of the
morphological and the biological tumor volume [37]. The
region of 11C-MET uptake was larger than that of
gadolinium-enhanced MRI in 31 of 39 cases (79%), and
in a majority of patients, the gadolinium-enhancement area
extended beyond the MET enhancement. A retrospective
study by Mahasittiwat et al. [38] confirmed these results
and found a significantly greater survival and distant
control rate in patients where the 11C-MET uptake did not
extend outside the clinical target volume. It has also been
reported that MR spectroscopy (MRS) can detect residual
cancer after surgery with a higher sensitivity and specificity
compared to MRI [41].
The development of medical image segmentation and
other image analysis techniques have been very rapid and
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Fig. 6 Comparison of mean tumor volumes for 18 patients and in
only 19 lesions where MRI, manual delineation, thresholding using
40% and 50% of the maximum intensity, as well as RG and SBR
techniques were able to adequately delineate the tumor volume. Error
bars indicate SD on the mean. Results are shown for the gross tumor
volume (GTV) delineated on MRI (GTVMRI) and PET-based GTVs
obtained by manual delineation of contours (GTVman), an isocontour
obtained using a fixed threshold of 40% (GTV40%) and 50%
(GTV50%) of the maximum signal intensity, signal-to-background
ratio (SBR)-based adaptive thresholding (GTVSBR), and region
growing (GTVRG) segmentation algorithms
Table 3 Summary of gross tumour volumes delineated using the different methods and overlap fractions (OFs) between various segmentation
tools
Segmentation Method Mean volume in cc
(95% CI)
Mean OFSBR
(95% CI)
Mean OFMRI
(95% CI)
P value Mean OFPET
(95% CI)
P value
GTVMRI 40.24 (30.37–50.11) – – – – –
GTVman 31.62 (20.30–40.95) 0.77 (0.66–0.88) 0.45 (0.33–0.56) NS 0.61 (0.52–0.71) < 0.001
GTVSBR 29.55 (22.02–37.08) – 0.44 (0.33–0.55) – 0.62 (0.50–0.74) –
GTV40% 39.90 (29.77–50.02) 0.99 (0.97–1.00) 0.54 (0.42–0.66) < 0.001 0.57 (0.46–0.67) < 0.001
GTV50% 24.37 (19.62–31.11) 0.73 (0.64–0.82) 0.36 (0.26–0.46) < 0.001 0.67 (0.56–0.79) < 0.001
GTVRG 26.35 (18.50–34.19) 0.74 (0.65–0.82) 0.37 (0.28–0.47) < 0.001 0.65 (0.53–0.78) < 0.001
GTVGF – 0.49 (0.33–0.65) 0.21 (0.11–0.31) NS 0.45 (0.25–0.66) < 0.01
GTV2.5 – 0.29 (0.16–0.41) 0.14 (0.06–0.21) NS 0.67 (0.49–0.86) < 0.01
The mean volumes are for 18 patients and only in 19 lesions where MRI, manual delineation, thresholding using 40% and 50% of the maximum
intensity, as well as RG and SBR techniques were able to adequately delineate the tumour volume (GF and SUV 2.5 were excluded in this
analysis). The p values are for OFs relative to OF of SBR (OFSBR) obtained by linear regression analysis. OFSBR is a comparison of OF within
PET defined volumes hence no estimate for MRI volume. The p values are reported for each segmentation technique relative to GTVSBR
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exciting, and there is every reason to believe the field will
move forward more rapidly in the near future with the
advent of better computing power and the unlimited
imagination of active researchers in the field. Our work
aimed at assessing various strategies for delineation of GTVs
for high-grade gliomas. A limited number of publications
reported on the comparative assessment of various image
segmentation techniques for GTV delineation [21, 23].
Automated segmentation techniques are important for
defining the target volume thus allowing alleviating the
difficult time-consuming manual procedures. Despite the
remarkable progress that automated image segmentation
has made during the last few years, performance valida-
tion in a clinical setting remains the most challenging
issue [15]. Evaluation and clinical validation of image
segmentation techniques and data quantification algo-
rithms is inherently difficult and sometimes unconvincing
particularly when applied to image-guided therapy [27]. A
survey of different methods proposed for evaluation of
image segmentation algorithms including the criteria for
choosing figures of merit is given elsewhere [42].
However, most of these techniques require the availability
of reference data where the ground truth is known. Further
validation within the framework of a prospective study
using in vivo macroscopic surgical specimen of oncologic
patients allowing thorough qualitative and quantitative
comparison of image segmentation results with the
surgical specimen considered as gold standard is clearly
needed but remains difficult in the case of brain tumors.
Conclusion
Besides the role of 18F-FET PET/CT in the delineation of
treatment volumes for radiation therapy treatment planning,
the technique had a major impact on further clinical
management of patients with high-grade gliomas. Eighteen
clinical image volumes were used to portray the contrasting
results obtained when using various PET-guided strategies
to delineate GTVs relative to MRI-guided delineation.
Overall, the majority of GTVs defined on PET-based
techniques were usually smaller than GTVMRI (67% of
cases). Yet, PET detected frequently tumors that are not
visible on MRI and added substantially tumor extension
outside the GTVMRI in six patients (33% of cases). The
choice of the most appropriate PET-based segmentation
algorithm is crucial, since it impacts both the volume and
shape of the ensuing GTV. SUV2.5 and GF segmentation
techniques performed poorly and should not be used for
GTV delineation. The SBR algorithm, as the only tech-
nique validated through a histologic study, can be used with
confidence as it has some practical advantages particularly
for adapting the threshold to the patient-specific SBR and for
limiting intra- and inter-observer dependence and variability.
With adequate delineation, PET may add considerably to
conventional MRI-guided GTV delineation.
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